Truscreen Group (ASX:TRU) Short Percentage of Float

View and export this data going back to 2021. Start your Free Trial

What is Truscreen Group Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Truscreen Group's Short Percentage of Float

For the Medical Devices subindustry, Truscreen Group's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Truscreen Group's Short Percentage of Float Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Truscreen Group's Short Percentage of Float falls into.

Truscreen Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (ASX:TRU) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

TRU:New Zealand

Address

C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010

Website

https://www.truscreen.com

Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.